

**Amendments to the Substitute Specification:**

**Replace the paragraph beginning at page 29, line 6, with the following rewritten paragraph:**

C1  
Promoters may be cell, tissue, organ or system specific, or may be non-specific. Using specific promoters, the expression of a bioactive agent or other polypeptide encoded by a structural gene to which the promoter is operably connected may be targeted to a desired cellular site. For example, in transgenic animals such as sheep, it can be envisaged that cells of the transgenic animal may contain a gene encoding a steroid receptor, preferably a steroid receptor linked to an epidermal specific promoter and a separate gene encoding, for example, epidermal growth factor (EGF) which is functionally linked to one or more insect hormone response elements and may or may not also be linked to epidermal specific promoter elements. On administration of the appropriate insect steroid hormone to the transgenic animal, the activated complex between the insect steroid receptor and insect steroid may bind to the one or more insect steroid hormone response element thereby inducing EGF production solely in epidermal cells which may give rise to defleecing. It is to be understood that this aspect of the invention is independent of the degree of thermostability of the insect steroid receptor. The same principal applies to expression of any bioactive molecule or reporter molecule in a specific cell type which is regulated by a transactivating complex between a steroid receptor complex and an appropriate insect steroid.

**Replace the paragraph beginning at page 30, line 11, with the following rewritten paragraph:**

C2  
For example, an SRE or a plurality of such elements may be operably linked to a promoter such as the ~~polyhedron~~ polyhedrin promoter, p10 promoter, MMTV promoter or SV40 promoter, to make transcription of a structural gene to which said promoter is operably connected responsive to the presence of a steroid bound to the insect receptor (which may act as a transcription factor). One or more insect SREs may be located within a promoter, and may replace sequences within a selected promoter which confer responsiveness to hormones or other agents which regulate promoter activity.

C<sup>2</sup> Where response elements are different they may lead to preferential binding of different insect steroids or analogues thereof such that a promoter may be differentially regulated.

**Replace the paragraph beginning at page 31, line 23, with the following rewritten paragraph:**

C<sup>3</sup> Suitable promoters for use in eukaryotic expression vectors include those capable of regulating expression in mammalian cells, insect cells such as Sf9 or Sf21. (*Spodoptera frugiperda*) cells, yeast cells and plant cells. Preferred promoters for expression in eukaryotic cells include the p10 promoter, MMTV promoter, ~~polyhedron~~ polyhedrin promoter, the SV40 early promoter and the cytomegalovirus (CMV-IE) promoter, promoters derived from immunoglobulin-producing cells (see, United States Patent No 4,663,281), polyoma virus promoters, and the LTR from various retroviruses (such as murine leukemia virus, murine or Rous sarcoma virus and HIV), amongst others ( See, *Enhancers and Eukaryotic Gene Expression*, Cold Spring Harbor Press, New York, 1983, which is incorporated herein by reference). Examples of other expression control sequences are enhancers or promoters derived from viruses, such as SV40, Adenovirus, Bovine Papilloma Virus, and the like.

**Replace the paragraph beginning at page 38, line 16, with the following rewritten paragraph:**

C<sup>4</sup> The present invention clearly extends to variants of said polypeptides, as described *supra*. The polypeptide may be substantially free of naturally associated insect cell components, or may be in combination with a partner protein which associates with the insect steroid receptor so as to confer enhanced affinity for insect steroid response elements, enhanced affinity for insect steroids or analogues thereof. For ~~Example~~ example, the amino acid sequences exemplified herein may be varied by the deletion, substitution or insertion of one or more amino acids.

**Replace the paragraph beginning at page 38, line 16, with the following rewritten paragraph:**

C5 One such variant polypeptide encompassed by the present invention comprises an "in-frame" fusion polypeptide between different regions of different insect receptor polypeptides. As exemplified herein, the present inventors have discovered that, by producing synthetic genes in which various domains of a base insect steroid receptor-encoding nucleotide sequence derived from a first source are interchanged or substituted with similar sequences derived from a second source (referred to as "domain swapping"), it is possible to modify the bioactivity of the insect steroid receptor encoded therefor. For example, the biological activity of the EcR polypeptide of the *L. cuprina* or *M. persicae* ecdysone receptor exemplified herein may be modulated by replacing portions of its C-terminal or N-terminal sequences with the equivalent domains from the EcR polypeptide of the *D. melanogaster* ecdysone receptor or alternatively, by swapping regions of the EcR polypeptides of the *L. cuprina* and *M. persicae* ecdysone receptors *per se*.

**Replace the paragraph beginning at page 52, line 14, with the following rewritten paragraph:**

Rationale for amplification primer design

C6 The nucleotide sequences of the primers Rdna3 (~~400~~15) (SEQ ID NO: 15) and Rdna4 (SEQ ID NO: 16) were derived from the amino acid sequence conserved between the DNA-binding domains of the EcR polypeptide subunits of the *D. melanogaster* and *C. tentans* ecdysone receptors. However, amino acid sequences homologous to two other members of the steroid receptor superfamily of *D. melanogaster*, *Drosophila* hormone receptor 3 (DHR3; Koelle, *et al.*, 1991) and *Drosophila* early gene (E75; Segraves and Hogness, 1990) were excluded from the primer designs, to reduce the possibility of amplifying the *L. cuprina* homologues of genes encoding DHR3 and/or E75 by PCR.